Diabetes Clinical Trial
Official title:
User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015
The user performance evaluation shows whether people with diabetes are able to obtain
accurate measurement results with a blood glucose monitoring system. In this study, user
performance evaluation will be performed for Contour Plus One (Ascensia Diabetes Care GmbH),
Accu-Chek Performa Connect (Roche Diabetes Care GmbH), FreeStyle Optium Neo (Abbott Diabetes
Care Inc.), OneTouch Select Plus (LifeScan Europe) based on ISO 15197:2013; EN ISO
15197:2015, clause 8.
For each BGMS, measurement procedures for user performance evaluation will be performed with
1 test meter and 1 reagent system lot by the study subjects.
The same meter and an additional test meter will be used for double measurements performed
by study personnel (with the same reagent system lot used by subjects).
Status | Completed |
Enrollment | 140 |
Est. completion date | February 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes - Signed informed consent form - Minimum age of 18 years - Subjects are legally competent and capable to understand character, meaning and consequences of the study. - If blood glucose values < 80 mg/dl or > 300 mg/dl shall be measured after short term alteration in insulin therapy: - Male or female with type 1 diabetes and intensified insulin therapy or insulin pump therapy. - Signature of subjects to document consent with these procedures on informed consent form. Exclusion Criteria: - Pregnancy or lactation period - Severe acute disease (at the study physician's discretion) - Severe chronic disease with potential risk during the test procedures (at the study physician's discretion) - Current constitution that compromises the subject's capability to participate in the study (at the study physician's discretion) - Being unable to give informed consent - < 18 years - Legally incompetent - Being committed to an institution (e.g. psychiatric clinic) - Language barriers potentially compromising an adequate compliance with study procedures - Dependent on investigator or sponsor - If blood glucose values < 80 mg/dl shall be measured after short term alteration in insulin therapy, subjects with type 1 diabetes, suffering from: - Coronary heart disease - Condition after myocardial infarction - Condition after cerebral events - Peripheral arterial occlusive disease - Hypoglycemia unawareness Inclusion and exclusion criteria defined by ISO 15197:2013; EN ISO 15197:2015: - Only subjects with diabetes type 1 or type 2 will be included. - Demographic data will be collected to demonstrate that subjects represent different ages, genders and education levels. - In deviation from ISO 15197:2013; EN ISO 15197:2015, included subjects may have participated in a study involving the BGMS, but must not yet have performed measurements with the BGMS according to their own statement for the last 3 years. - In addtition, included subjects did not use the BGMS being evaluated at home for the last 3 years according to their own statement. - In order to ensure that capillary blood samples meet the requirements indicated in the manufacturer's labelling, - a physician will review the subjects' anamnesis and medication and check for interfering substances indicated in the manufacturer's labelling. - the hematocrit value of each subject will be checked to be within the range indicated in the manufacturer's labelling (hematocrit determination before or after the measurement procedure). |
Country | Name | City | State |
---|---|---|---|
Germany | Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Ulm |
Lead Sponsor | Collaborator |
---|---|
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Ascensia Diabetes Care |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | System accuracy criteria (see description) | Acceptance criteria defined by ISO 15197:2013 (E) / EN ISO 15197:2015 will be applied: 95 % of the individual glucose measured values shall fall within ± 15 mg/dl (0.83 mmol/l) of the measured values of the comparison measurement procedure at glucose concentrations < 100 mg/dl (5.55 mmol/l) and within ± 15 % at glucose concentrations = 100 mg/dl (5.55 mmol/l). |
For each subject, the experimental phase has an expected duration of up to 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |